Neurocrine Biosciences | NBIX - Interest Expense On Debt


Neurocrine Biosciences reported $1.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Cytokinetics USD 33.34M 3M Mar/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 240M 15M Mar/2026
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Incyte USD 569K 13K Mar/2026
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 671M 40M Mar/2026
Prothena USD 349.89M 347.27M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Repligen USD 5.58M 83K Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xoma USD 3.4M 150K Jun/2024